CNSide Diagnostics, a wholly-owned subsidiary of Plus Therapeutics (PSTV), has signed a national agreement with Humana (HUM), effective October 29, covering approximately 16M people throughout the United States, to provide the CNSide Cerebrospinal Fluid Tumor Cell Enumeration laboratory developed test. This brings CNSide CSF TCE LDT total policy coverage to 67M people.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PSTV:
- Plus Therapeutics Gains Nasdaq Extension for Compliance
- Plus receives additional extension to regain compliance with Nasdasq
- Plus Therapeutics highlights ReSPECT-LM trial results at SITC meeting
- Buy Rating for Plus Therapeutics: Growth Potential Driven by CNSide Launch and Strategic Positioning
- Plus Therapeutics price target lowered to $2 from $3 at H.C. Wainwright